145 related articles for article (PubMed ID: 10543747)
1. Civamide (cis-capsaicin) for treatment of primary or recurrent experimental genital herpes.
Bourne N; Bernstein DI; Stanberry LR
Antimicrob Agents Chemother; 1999 Nov; 43(11):2685-8. PubMed ID: 10543747
[TBL] [Abstract][Full Text] [Related]
2. Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes.
Bernstein DI; Cardin RD; Bravo FJ; Earwood J; Clark JR; Li Y; Mishra P; Li C; Nayak BP; Miller AT; Wu TY; Cooke MP; Valiante NM
Antivir Chem Chemother; 2014 Apr; 23(5):189-96. PubMed ID: 23232327
[TBL] [Abstract][Full Text] [Related]
3. Suppression of recurrent genital herpes simplex virus type 2 infection by Rhus javanica in guinea pigs.
Nakano M; Kurokawa M; Hozumi T; Saito A; Ida M; Morohashi M; Namba T; Kawana T; Shiraki K
Antiviral Res; 1998 Jul; 39(1):25-33. PubMed ID: 9754947
[TBL] [Abstract][Full Text] [Related]
4. Capsaicin-sensitive peptidergic neurons are involved in the zosteriform spread of herpes simplex virus infection.
Stanberry LR; Bourne N; Bravo FJ; Bernstein DI
J Med Virol; 1992 Oct; 38(2):142-6. PubMed ID: 1334128
[TBL] [Abstract][Full Text] [Related]
5. Capsaicin interferes with the centrifugal spread of virus in primary and recurrent genital herpes simplex virus infections.
Stanberry LR
J Infect Dis; 1990 Jul; 162(1):29-34. PubMed ID: 2162369
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs.
Bernstein DI; Bravo FJ; Pullum DA; Shen H; Wang M; Rahman A; Glazer RI; Cardin RD
Antivir Chem Chemother; 2015 Feb; 24(1):19-27. PubMed ID: 26149263
[TBL] [Abstract][Full Text] [Related]
7. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Rose WA; Tuthill C; Pyles RB
Int J Antimicrob Agents; 2008 Sep; 32(3):262-6. PubMed ID: 18619817
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic effect of gefin, a new antiviral drug, in experimental genital herpes ].
Alimbarova LM; Barinskiĭ IF; Kuz'min KK
Vopr Virusol; 2002; 47(1):34-7. PubMed ID: 11852781
[TBL] [Abstract][Full Text] [Related]
9. Oral and topical treatment of experimental HSV-1 genital herpes with (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Sim IS
J Antimicrob Chemother; 1984 Aug; 14 Suppl A():111-8. PubMed ID: 6541647
[TBL] [Abstract][Full Text] [Related]
10. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.
Pyles RB; Higgins D; Chalk C; Zalar A; Eiden J; Brown C; Van Nest G; Stanberry LR
J Virol; 2002 Nov; 76(22):11387-96. PubMed ID: 12388699
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes.
Jennings R; Smith TL; Myhren F; Phillips J; Sandvold ML
Antimicrob Agents Chemother; 1999 Jan; 43(1):53-61. PubMed ID: 9869565
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antioxidant healing formulations in topical therapy of experimental cutaneous and genital herpes simplex virus infections.
Sheridan J; Kern E; Martin A; Booth A
Antiviral Res; 1997 Dec; 36(3):157-66. PubMed ID: 9477116
[TBL] [Abstract][Full Text] [Related]
13. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
14. [Recurrent genital herpes].
Holub M; Labská K; Roubalová K
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):52-9. PubMed ID: 18756434
[TBL] [Abstract][Full Text] [Related]
15. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time.
Benedetti JK; Zeh J; Corey L
Ann Intern Med; 1999 Jul; 131(1):14-20. PubMed ID: 10391810
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations.
Bernstein DI; Ireland J; Bourne N
Antiviral Res; 2000 Sep; 47(3):159-69. PubMed ID: 10974368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):501-13. PubMed ID: 10772730
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes.
Bourne N; Bravo FJ; Ashton WT; Meurer LC; Tolman RL; Karkas JD; Stanberry LR
Antimicrob Agents Chemother; 1992 Sep; 36(9):2020-4. PubMed ID: 1329638
[TBL] [Abstract][Full Text] [Related]
20. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
